Medtronic plc

NYSE MDT

Medtronic plc Receivables for the quarter ending October 25, 2024: USD 6.26 B

Medtronic plc Receivables is USD 6.26 B for the quarter ending October 25, 2024, a 5.49% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.
  • Medtronic plc Receivables for the quarter ending October 27, 2023 was USD 5.93 B, a 5.47% change year over year.
  • Medtronic plc Receivables for the quarter ending October 28, 2022 was USD 5.63 B, a 2.42% change year over year.
  • Medtronic plc Receivables for the quarter ending October 29, 2021 was USD 5.49 B, a 2.71% change year over year.
  • Medtronic plc Receivables for the quarter ending October 30, 2020 was USD 5.35 B, a -12.59% change year over year.
Key data
Date Receivables Inventory Goodwill Total Assets
Market news
Loading...
NYSE: MDT

Medtronic plc

CEO Mr. Geoffrey Straub Martha
IPO Date May 2, 1973
Location Ireland
Headquarters 20 On Hatch
Employees 95,000
Sector Health Care
Industries
Description

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Similar companies

PODD

Insulet Corporation

USD 267.04

-0.35%

DXCM

DexCom, Inc.

USD 79.17

-0.84%

EW

Edwards Lifesciences Corporation

USD 71.04

-0.07%

SYK

Stryker Corporation

USD 362.80

0.50%

ABT

Abbott Laboratories

USD 113.02

-0.15%

ZBH

Zimmer Biomet Holdings, Inc.

USD 104.71

-0.74%

TNDM

Tandem Diabetes Care, Inc.

USD 35.79

-1.16%

BSX

Boston Scientific Corporation

USD 95.65

1.10%

ALGN

Align Technology, Inc.

USD 210.46

-1.51%

StockViz Staff

January 15, 2025

Any question? Send us an email